InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Key Highlights
- ➤Merger-related Nasdaq share issuance and change of control approved with 97.295% support
- ➤One-for-ten share consolidation completed, reducing outstanding shares to approximately 549,374
- ➤Company legally changed its name to Mentari Therapeutics, Inc.
- ➤Post-consolidation Nasdaq trading under INM expected to begin November 5, 2026
- ➤Merger remains subject to satisfaction or waiver of closing conditions
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, confirmed that, at its annual general and special meeting of shareholders held today (the "Meeting"), the matters put forward before shareholders for consideration and approval, as set out in the Company's proxy statement/prospectus and management information circular dated October 1, 2026 (the "Circular"), were voted upon by the Company's shareholders. A total of 3,630,088 common shares of the Company (each, a "Common Share"), representing approximately 66.08% of the Company's 5,493,735 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
Get started
Create a free account to read the full story.